SCHEMBL831183

SCHEMBL831183

O=CC(C=O)(C=Cc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.55
HDAC1 Q13547 4/20 0.47
ALDH1A1 P00352 4/20 0.47
LMNA P02545 3/20 0.47
HDAC3 O15379 3/20 0.47
HDAC4 P56524 3/20 0.47
HDAC2 Q92769 3/20 0.47
HDAC8 Q9BY41 3/20 0.47
HDAC6 Q9UBN7 3/20 0.47
PLIN1 O60240 2/20 0.47
MAPT P10636 2/20 0.47
RECQL P46063 2/20 0.47
PLIN5 Q00G26 2/20 0.47
ABHD5 Q8WTS1 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
CYP1A2 P05177 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1236317 0.83 CYP2C19 (0.46) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL1618355 0.75 CYP2C19 (0.58) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL28748361 0.73 CYP2C19 (0.67) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL6067666 0.73 CYP2C19 (0.67) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL30583099 0.73 CYP2C19 (0.56) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL28655879 0.73 CYP2C19 (0.56) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL1579975 0.71 ALDH1A1 (0.46) CYP2C19HDAC1ALDH1A1LMNAHDAC3
SCHEMBL3906269 0.71 CYP2C19 (0.53) CYP2C19HDAC1ALDH1A1LMNAHDAC3
(Z)-1,2-Diphenylethene SCHEMBL4532649 0.70 HDAC1 (0.67) HDAC1ALDH1A1LMNAHDAC3HDAC4
(Z)-1,2-Diphenylethene SCHEMBL980839 0.70 HDAC1 (0.67) HDAC1ALDH1A1LMNAHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2028240-B1 Phase change ink compositions XEROX CORP (US) 2016-02-10 EP disclosed
US-20150145920-A1 METHOD OF JETTING INK XEROX CORPORATION (US) 2015-05-28 US disclosed
US-9022546-B1 Method of jetting ink XEROX CORPORATION (US) 2015-05-05 US disclosed
US-8142557-B2 Radiation curable ink containing gellant and radiation curable wax XEROX CORPORATION (US) 2012-03-27 US disclosed
US-7887176-B2 High image quality in inkjet printing onto flexible packaging substrates of polyester, polypropylene, and aluminum foil, can be significantly improved by the use of radiation curable gel based phase change inks; not requiring pinning of the ink during color printing or nitrogen inerting during curing XEROX CORPORATION (US) 2011-02-15 US disclosed
EP-2223803-A1 Preparation of flexographic printing masters using an additive process Xerox Corporation (US) 2010-09-01 EP disclosed
US-20100215865-A1 PREPARATION OF FLEXOGRAPHIC PRINTING MASTERS USING AN ADDITIVE PROCESS XEROX CORPORATION (US) 2010-08-26 US disclosed
US-7504531-B2 Processes for preparing difunctional compounds XEROX CORPORATION (US) 2009-03-17 US disclosed
EP-2028240-A1 Phase Change Ink Compositions Xerox Corporation (US) 2009-02-25 EP disclosed
US-20080218570-A1 IMAGING ON FLEXIBLE PACKAGING SUBSTRATES XEROX CORPORATION (US) 2008-09-11 US disclosed
US-20080204538-A1 PRINTING ON CORRUGATED SUBSTRATES XEROX CORPORATION (US) 2008-08-28 US disclosed
US-20080000384-A1 RADIATION CURABLE INK CONTAINING GELLANT AND RADIATION CURABLE WAX XEROX CORPORATION (US) 2008-01-03 US disclosed
US-20070255071-A1 PROCESSES FOR PREPARING DIFUNCTIONAL COMPOUNDS XEROX CORPORATION (US) 2007-11-01 US disclosed
US-20070255038-A1 Processes for preparing difunctional compounds XEROX CORPORATION (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070255071-A1 PROCESSES FOR PREPARING DIFUNCTIONAL COMPOUNDS ABL2, ABL1, PAICS CYP2C19 902/4885HDAC1 3094/4885ALDH1A1 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.